2016
DOI: 10.1097/wnr.0000000000000548
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: The incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are growth factors. GLP-1 mimetics are on the market as treatments for type 2 diabetes. Both GLP-1 and GIP mimetics have shown neuroprotective properties in previous studies. In addition, the GLP-1 mimetic exendin-4 has shown protective effects in a clinical trial in Parkinson's disease (PD) patients. Novel GLP-1/GIP dual-agonist peptides have been developed to treat diabetes. Here, we report the neuroprotectiv… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
50
0
2

Year Published

2016
2016
2017
2017

Publication Types

Select...
3

Relationship

2
1

Authors

Journals

citations
Cited by 58 publications
references
References 37 publications
3
50
0
2
Order By: Relevance
“…It is of interest to note that grip strength was very much impaired on day 1 after MPTP treatment, in contrast to rotarod performance. This result is in line with previous results using these techniques (Cao et al, 2016). This difference demonstrates that the toxin affects muscle strength to a much higher degree than sensorimotor coordination as measured in the rotarod.…”
Section: Discussionsupporting
confidence: 83%
See 2 more Smart Citations
“…It is of interest to note that grip strength was very much impaired on day 1 after MPTP treatment, in contrast to rotarod performance. This result is in line with previous results using these techniques (Cao et al, 2016). This difference demonstrates that the toxin affects muscle strength to a much higher degree than sensorimotor coordination as measured in the rotarod.…”
Section: Discussionsupporting
confidence: 83%
“…compared to lirglutide (Finan et al, 2013). One of these dual agonists that we named DA-JC1 reduced the MPTP-induced impairment of motor control, increased the level of TH positive neurons in the substantia nigra, reduced the activation of microglia and astrocytes, enhanced growth factor cell signalling such as Pi3k activity and Bcl-2 and BDNF levels, while reducing pro-apoptotic BAX signalling (Cao et al, 2016;Ji et al, 2016b). We also tested DA-JC1 in the 6-OHDA rat model of PD where it displayed good neuroprotective effects and enhanced dopamine levels in the striatum (Jalewa et al, 2017).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Currently, there are two published studies that demonstrated the neuroprotective effects of DA-JC1 in the MPTP mouse model of PD by increasing the expression of BDNF (Ji et al, 2016b), increasing the number of TH-positive neurons in the substantia nigra, and reducing the activation of astroglia and microglia (Cao et al, 2016). In addition, DA-JC1 also showed more neuroprotective effects than a GLP-1R agonist in transient focal cerebral ischemia in the rat (Han et al, 2016).…”
Section: Effects Of Dual Agonist On Neurodegenerative Diseasesmentioning
confidence: 96%
“…При этом применение инкрети-номиметиков сопровождалось ингибированием ак-тивации микроглии [22,30] с преобладанием проти-вовоспалительного М2 фенотипа, а также снижени-ем экспрессии генов провоспалительных цитокинов (IL-1β, TNF-α и MCP-1 -мощного фактора хемо-таксиса моноцитов) [24]. На модели хронического воспаления (облучение животного Х-лучами) лира-глутид снижал активацию микроглии в коре и зубча-той извилине, снижал содержание провоспалитель-ных цитокинов (IL-6, IL-12, IL-1β) в астроцитах, уменьшал уровень отека и инфильтрацию ткани мозга нейтрофилами [20].…”
Section: точки приложения действия инкретиномиметиков при нейродегенеunclassified